SC-type Remsima starts to aim for TNF-α inhibitor market

Published: 2016-05-10 14:01:33

Updated: 2016-05-10 14:01:33

Celltrion started to conduct a clinical trial of the SC-type of Remsima, an autoimmune treatment, expanding its product competitiveness in the TNF-α inhibitor market. The company announced acquisition of the Phase 1 clinical trial approval of the autoimmune treatment ‘CT-P13 SC(hereinafter referring to Remsima SC)’ from the Korean Ministry of Food and Drug Safety on the 4^th of May.

The purpose...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.